

On November 19, 2023, at the Immunotherapy Session of the 2023 Fourth Precision Medicine Conference held at the Guangzhou Yuexiu International Convention Center, our Chief Scientist Professor Wang Jianxun delivered a presentation titled "Establishment of a Standardized and Normalized GMP Industrial Production System for Retroviral Vectors." On behalf of Shenzhen Cell Valley, he also participated in a strategic cooperation signing ceremony with T-Cell Immune (Guangzhou) Technology Co., Ltd. The two parties will collaborate on the development of retroviral vector-based TCR-T cell therapy pipelines and engage in comprehensive cooperation in IIT clinical research and new drug IND applications, deepening the research and development of TCR-T cell therapy. Through Shenzhen Cell Valley's core technology—efficient and stable retroviral vectors—they aim to push TCR-T research and clinical application to a new level and make positive contributions to truly benefiting cancer patients.

About T-Cell Immune (Guangzhou) Technology Co., Ltd.
T-Cell Immune (Guangzhou) Technology Co., Ltd. focuses on the R&D, production, and services of precision tumor T-cell immunotherapy diagnostic and therapeutic products with significant application prospects, such as TCR-T cell anti-cancer immunotherapy. The company's founder and chairman, Professor Li Liangping, serves as Director of the Clinical Oncology Research Institute at the First Clinical Medical College of Jinan University. The company's core team members all have years of overseas study, biopharmaceutical R&D experience, or long-term pharmaceutical enterprise production and operation management experience. The company possesses a tumor immune cell therapy technology platform, a single-cell sequencing technology and synthetic biology platform, an experimental animal and biocomputing platform, and tumor TIL/organoid culture technology. The company has core R&D laboratories and T-cell laboratories in the South China New Materials Innovation Park in Guangzhou High-tech Development Zone, and has built a 1,000-square-meter GMP cell laboratory and production and testing workshops. The company's first TCR-T product has achieved phased results, capable of targeting various solid tumors including gastric cancer, lung cancer, and breast cancer, with anti-cancer activity higher than similar foreign products; this product is currently undergoing IIT clinical research on cancer patients at a renowned tertiary hospital in Guangzhou.
T-Cell Immune (Guangzhou) Technology Co., Ltd. is committed to providing personalized precision tumor immunotherapy treatment plans for every cancer patient and aims to become a leader in the precision tumor T-cell immunotherapy diagnostic and therapeutic market.
Scan to follow our latest news Working hours: Monday to Friday, 9:00-18:00
Contact:Ms. Lai
Email:laijiaqi@rodael.com
Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)